title: Management of oral secretions in neurological disease.
abstract: Sialorrhoea is a common and problematic symptom that arises from a range of neurological conditions associated with bulbar or facial muscle dysfunction. Drooling can significantly affect quality of life due to both physical complications such as oral chapping, and psychological complications such as embarrassment and social isolation. Thicker, tenacious oral and pharyngeal secretions may result from the drying management approach to sialorrhoea. The management of sialorrhoea in neurological diseases depends on the underlying pathology and severity of symptoms. Interventions include anticholinergic drugs, salivary gland-targeted radiotherapy, salivary gland botulinum toxin and surgical approaches. The management of thick secretions involves mainly conservative measures such as pineapple juice as a lytic agent, cough assist, saline nebulisers and suctioning or mucolytic drugs like carbocisteine. Despite a current lack of evidence and variable practice, management of sialorrhoea should form a part of the multidisciplinary approach needed for long-term neurological conditions.
authors.affiliation: Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: McGeachan
authors.affiliation: Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK c.j.mcdermott@sheffield.ac.uk.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Mcdermott
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D019468:Disease Management; D006801:Humans; D009422:Nervous System Diseases / Q000150:complications*; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012798:Sialorrhea / Q000209:etiology* / Q000628:therapy*
chemical_list: D018680:Cholinergic Antagonists; D019274:Botulinum Toxins, Type A